Skip to main
MDAI

MDAI Stock Forecast & Price Target

MDAI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Spectral AI Inc. is poised for significant financial growth, with expectations of revenue increasing at a compound annual growth rate (CAGR) of 69% or more from fiscal year 2026 through fiscal year 2030 following the commercial launch of its DeepView System. The company's licensing model is projected to generate recurring revenue with high margins, positioning Spectral AI for predictable and stable growth within the MedTech sector. Additionally, improvements in efficiency demonstrated in clinical studies further bolster confidence in the company's operational effectiveness and market potential.

Bears say

Spectral AI Inc. has lowered its fiscal year 2025 revenue guidance to approximately $18.5 million, reflecting a decline of about 37.6% year-over-year from a prior estimate of $21.5 million, primarily due to delays related to the BARDA contract and the impact of the government shutdown. The company anticipates further revenue declines in fiscal year 2026, although specific guidance has not been provided, indicating a pessimistic outlook for continued revenue growth. Additionally, extended clinical and regulatory development timelines may result in decreased BARDA-related revenue, contributing to the overall negative financial projection.

MDAI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Spectral AI Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Spectral AI Inc (MDAI) Forecast

Analysts have given MDAI a Strong Buy based on their latest research and market trends.

According to 2 analysts, MDAI has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Spectral AI Inc (MDAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.